## Satoshi Oeda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2401417/publications.pdf

Version: 2024-02-01

777949 721071 23 553 13 23 citations h-index g-index papers 25 25 25 1054 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clinical Gastroenterology and Hepatology, 2023, 21, 370-379.	2.4	30
2	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatology Communications, 2022, 6, 120-132.	2.0	60
3	Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Scientific Reports, 2022, 12, 1517.	1.6	10
4	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics, 2021, 11, 132.	1.3	18
5	Effect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease. Scientific Reports, 2021, 11, 15641.	1.6	4
6	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. Journal of Gastroenterology, 2020, 55, 428-440.	2.3	50
7	Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics, 2020, 10, 940.	1.3	44
8	Metabolomic/lipidomicâ€based analysis of plasma to diagnose hepatocellular ballooning in patients with nonâ€alcoholic fatty liver disease: A multicenter study. Hepatology Research, 2020, 50, 955-965.	1.8	12
9	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and nonâ€invasive tests for the diagnosis of advanced liver fibrosis in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2020, 50, 682-692.	1.8	32
10	Discordant pathological diagnosis of nonâ€alcoholic fatty liver disease: A prospective multicenter study. JGH Open, 2020, 4, 497-502.	0.7	22
11	Diagnostic accuracy of FibroScanâ€AST score to identify nonâ€alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with nonâ€alcoholic fatty liver disease: Comparison between M and XL probes. Hepatology Research, 2020, 50, 831-839.	1.8	32
12	Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects. Internal Medicine, 2020, 59, 169-174.	0.3	3
13	Recommendations from primary care physicians, family, friends and work colleagues influence patients' decisions related to hepatitis screening, medical examinations and antiviral treatment. Experimental and Therapeutic Medicine, 2020, 19, 2973-2982.	0.8	6
14	Predictors of hepatocellular carcinoma recurrence associated with the use of directâ€acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. Cancer Medicine, 2019, 8, 2646-2653.	1.3	27
15	Categorization and Characterization of Activities Designed to Help Health-care Professionals Involved in Hepatitis Care Increase Their Awareness of the Disease: The Classification of Hepatitis Medical Care Coordinators. Internal Medicine, 2019, 58, 1825-1834.	0.3	4
16	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatology International, 2019, 13, 293-301.	1.9	38
17	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. Hepatology Research, 2018, 48, E252-E262.	1.8	37
18	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. Scientific Reports, 2018, 8, 7958.	1.6	38

## SATOSHI OEDA

#	Article	IF	CITATIONS
19	"Weariness―and "unpleasantness―reduce adherence to branchedâ€chain amino acid granules among Japanese patients with liver cirrhosis: results of a singleâ€center crossâ€sectional survey. Hepatology Research, 2017, 47, E169-E177.	1.8	4
20	Reducing the mortality rate of hepatitis and liver cancer in Japan. Journal of General and Family Medicine, 2017, 18, 205-211.	0.3	6
21	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterology, 2017, 17, 96.	0.8	65
22	Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival. Internal Medicine, 2016, 55, 2749-2758.	0.3	10
23	The aging of subjects with hepatitis C virus and the impact of dual oral therapy for elder hepatitis C patients. Acta Hepatologica Japonica, 2015, 56, 273-279.	0.0	1